Technical Data
B0003-05B1
Bacillus anthracis LF, ID (Lethal Factor, LF, Anthrax Lethal Toxin Endopeptidase Component, lef, pXO1-107, BXA0172, GBAA_pXO1_0172)
Description:
Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed, which allows the translocation of LF and EF into the cytoplasm. LF (M.W 89kD) is the primary toxin of anthrax and functions as a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near their amino terminus, interfering with MAPK signaling and inducing apoptosis.

Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
50ug-20CBlue IceRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide corresponding to 16aa in the internal sequence of the Anthrax lethal factor protein.
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, 0.02% sodium azide.
Specificity:
Recognizes Bacillus anthracis lethal factor.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Schwartz, MN. et al. New Engl. J. Med. 345, 1621 (2001). 2. Moayeri, M. et al. Curr. Opin. Microbiol. 7, 19 (2004). 3. Bradley, KA. et al. Nature 414, 225 (2001). 4. Scobie, HM. et al. Proc. Natl. Acad. Sci. USA 100, 5170 (2003). 5. Singh, Y. et al. Infect. Immun. 67, 1853 (1999). 6. Duesbury, N. et al. Science 280, 734 (1998).